Lumateperone news

All news on Lumateperone (also known as CAPLYTA): plants, production capacities, investments and involved companies.

4 May 2026

Johnson & Johnson: CAPLYTA tops adjunctive MDD antipsychotics in network meta-analysis

Network meta-analysis of 10 trials found an adjunctive atypical antipsychotic superior on MADRS change, response, remission and CGI‑S, with no significant weight gain and favorable tolerability.
27 April 2026

Johnson & Johnson: FDA approves CAPLYTA sNDA to reduce schizophrenia relapse risk

FDA approved sNDA for CAPLYTA (lumateperone) to prevent relapse in schizophrenia. Phase 3 randomized‑withdrawal: 63% lower relapse risk (HR 0.37); 84% relapse‑free at 6 months; safety consistent.
16 January 2026

Johnson & Johnson's CAPLYTA® Shows Promise for Remission in Major Depressive Disorder

CAPLYTA® nearly doubles remission rates in major depressive disorder when used with antidepressants, showing sustained benefits over six months in clinical studies.
13 January 2026

Johnson & Johnson Presents New Depression Data at 2026 ACNP Meeting

11 abstracts on neuropsychiatry, including MDD and TRD, will be presented, highlighting clinical and preclinical research, AI tools, and novel therapeutic mechanisms.
6 November 2025

Johnson & Johnson's CAPLYTA® Approved by FDA for Major Depressive Disorder Treatment

FDA approves CAPLYTA® as adjunctive therapy for major depressive disorder, showing significant symptom improvement and safety in trials, with potential for remission.

Who will be producing Lumateperone in the future?

Find out with chemXplore Alpha

Learn more